Pascal and Francis Bibliographic Databases

Help

Search results

Your search

au.\*:("YANG, Sherry X")

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 11 of 11

  • Page / 1

Export

Selection :

  • and

Targeting Notch signaling pathway in cancer: Clinical development advances and challengesTAKEBE, Naoko; NGUYEN, Dat; YANG, Sherry X et al.Pharmacology & therapeutics (Oxford). 2014, Vol 141, Num 2, pp 140-149, issn 0163-7258, 10 p.Article

Designing Phase 0 Cancer Clinical Trials : FOCUSON Phase O Clinical trialsMURGO, Anthony J; KUMMAR, Shivaani; HOLLINGSHEAD, Melinda et al.Clinical cancer research. 2008, Vol 14, Num 12, pp 3675-3682, issn 1078-0432, 8 p.Article

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancerWEDAM, Suparna Bonthala; LOW, Jennifer A; PLEHN, Jonathan et al.Journal of clinical oncology. 2006, Vol 24, Num 5, pp 769-777, issn 0732-183X, 9 p.Article

Akt Phosphorylation at Ser473 Predicts Benefit of Paclitaxel Chemotherapy in Node-Positive Breast CancerYANG, Sherry X; COSTANTINO, Joseph P; KIM, Chungyeul et al.Journal of clinical oncology. 2010, Vol 28, Num 18, pp 2974-2981, issn 0732-183X, 8 p.Article

Gene expression patterns and profile changes pre- and post- erlotinibtreatment in patients with metastatic breast cancerYANG, Sherry X; SIMON, Richard M; TAN, Antoinette R et al.Clinical cancer research. 2005, Vol 11, Num 17, pp 6226-6232, issn 1078-0432, 7 p.Article

p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancerYANG, Sherry X; STEINBERG, Seth M; NGUYEN, Dat et al.International journal of oncology. 2011, Vol 38, Num 5, pp 1445-1452, issn 1019-6439, 8 p.Article

Gene Expression Profile and Angiogenic Marker Correlates with Response to Neoadjuvant Bevacizumab Followed by Bevacizumab plus Chemotherapy in Breast CancerYANG, Sherry X; STEINBERG, Seth M; NGUYEN, Dat et al.Clinical cancer research (Print). 2008, Vol 14, Num 18, pp 5893-5899, issn 1078-0432, 7 p.Article

Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF TherapiesBRAUER, Matthew J; GUANGLEI ZHUANG; MODRUSAN, Zora et al.Clinical cancer research (Print). 2013, Vol 19, Num 13, pp 3681-3692, issn 1078-0432, 12 p.Article

Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarrayYANG, Sherry X; HEWITT, Stephen M; STEINBERG, Seth M et al.Oncology reports. 2007, Vol 17, Num 2, pp 281-287, issn 1021-335X, 7 p.Article

Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanesDENDULURI, Neelima; LOW, Jennifer A; LEE, James J et al.Journal of clinical oncology. 2007, Vol 25, Num 23, pp 3421-3427, issn 0732-183X, 7 p.Article

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancerLOW, Jennifer A; WEDAM, Suparna B; SWAIN, Sandra M et al.Journal of clinical oncology. 2005, Vol 23, Num 12, pp 2726-2734, issn 0732-183X, 9 p.Conference Paper

  • Page / 1